203 related articles for article (PubMed ID: 23656508)
1. Phosphodiesterase-4 inhibitor therapy for lung diseases.
Beghè B; Rabe KF; Fabbri LM
Am J Respir Crit Care Med; 2013 Aug; 188(3):271-8. PubMed ID: 23656508
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
4. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
5. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.
Diamant Z; Spina D
Pulm Pharmacol Ther; 2011 Aug; 24(4):353-60. PubMed ID: 21255672
[TBL] [Abstract][Full Text] [Related]
6. Selective PDE inhibitors as novel treatments for respiratory diseases.
Page CP; Spina D
Curr Opin Pharmacol; 2012 Jun; 12(3):275-86. PubMed ID: 22497841
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Giembycz MA; Newton R
Handb Exp Pharmacol; 2011; (204):415-46. PubMed ID: 21695651
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
9. The potential of PDE4 inhibitors in asthma or COPD.
Spina D
Curr Opin Investig Drugs; 2000 Oct; 1(2):204-13. PubMed ID: 11249575
[TBL] [Abstract][Full Text] [Related]
10. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
11. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.
Michalski JM; Golden G; Ikari J; Rennard SI
Clin Pharmacol Ther; 2012 Jan; 91(1):134-42. PubMed ID: 22130119
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
Gross NJ; Giembycz MA; Rennard SI
COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
[TBL] [Abstract][Full Text] [Related]
13. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions.
Parikh N; Chakraborti AK
Curr Med Chem; 2016; 23(2):129-41. PubMed ID: 26572614
[TBL] [Abstract][Full Text] [Related]
15. Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease.
Facchinetti F; Civelli M; Singh D; Papi A; Emirova A; Govoni M
Front Pharmacol; 2021; 12():740803. PubMed ID: 34887752
[TBL] [Abstract][Full Text] [Related]
16. Type 4 phosphodiesterase-dependent pathways: role in inflammatory processes.
Jacob C; Martin-Chouly C; Lagente V
Therapie; 2002; 57(2):163-8. PubMed ID: 12185965
[TBL] [Abstract][Full Text] [Related]
17. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
18. Is PDE4 too difficult a drug target?
Higgs G
Curr Opin Investig Drugs; 2010 May; 11(5):495-8. PubMed ID: 20419594
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterases as therapeutic targets for respiratory diseases.
Zuo H; Cattani-Cavalieri I; Musheshe N; Nikolaev VO; Schmidt M
Pharmacol Ther; 2019 May; 197():225-242. PubMed ID: 30759374
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.
Tenor H; Hatzelmann A; Beume R; Lahu G; Zech K; Bethke TD
Handb Exp Pharmacol; 2011; (204):85-119. PubMed ID: 21695636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
